In other news, Novavax(NVAX) said Tuesday that its experimental avian influenza vaccine produced a strong immune response in humans in a phase I/IIa study. The company said the vaccine showed strong antibody activity at three levels of dosing, with the highest dose producing the greatest effect.
Novavax said its manufacturing process makes it possible to potentially produce and distribute a vaccine matched to a pandemic strain in time to interrupt and/or halt a pandemic. The company, which is collaborating with GE Healthcare, said that because process involves recombinant technology and doesn't require a live influenza virus, a vaccine can be manufactured within 10 to 12 weeks of identification of a pandemic strain, roughly half the time required to manufacture egg-based vaccines. Novavax shares were off by 6 cents, or 2%, at $2.91.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
Connect with TheStreet
 |
 |
-
Lloyds predicts a profitable 2010
BBC
-
Rio Tinto signs China mines deal
BBC
-
The politicization of economic problems
Credit Writedowns
-
Apple Races to Secure iPad Deals
The Wall Street Journal.
-
Greenspan Concedes Fed Failed to Gauge Bubble
New York Times
-
Asian Stocks Head for 6th Week of Gains
New York Times
-
Foreclosed Homes on the Rise
The Wall Street Journal.
-
BOJ Statistics Chief To Appear At Parliament Committee From 0425 GMT
FOXBusiness.com
-
Yale Cuts Hedge Funds to Hold More Private Equity, Real Assets
BusinessWeek Online
-
DataQuick: California Bay Area Sales decline Slightly
Calculated Risk
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,779.17 | 1,165.82 | 2,391.28 | 36.72 |
Oil *
81.41
|
|
UP
45.50
|
DOWN
0.39
|
UP
2.19
|
UP
0.30
|
10 Yr
3.67%
SPDR Gold
110.34
|
|
+0.42%
|
-0.03%
|
+0.09%
|
+0.82%
|
Data delayed 20 minutes |
More From TheStreet
Latest Headlines
Brokerage Partners
Sponsored Links
